Macrogenics (MGNX) Long-Term Deferred Tax (2014)

Macrogenics (MGNX) posted quarterly Long-Term Deferred Tax of $1.6 million for Q4 2014.

Macrogenics (MGNX) Long-Term Deferred Tax (2014) Analysis & Trends

Macrogenics (MGNX) has reported Long-Term Deferred Tax for 1 consecutive years, with $1.6 million the latest figure, recorded in Q4 2014.

In Q4 2014, Long-Term Deferred Tax changed N/A year-over-year to $1.6 million; the TTM figure through Dec 2014 stood at $1.6 million (changed N/A YoY), while the FY2014 annual figure was $1.6 million, changed N/A from the prior year.
Long-Term Deferred Tax steadied at $1.6 million in Q4 2014 per MGNX's latest filing.
Across five years, Long-Term Deferred Tax topped out at $1.6 million in Q4 2014 and bottomed at $1.6 million in Q4 2014.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Macrogenics	268.22 Mn	201.71 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2014	1.60 Mn